Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed CFO
Quarterly results
Appointed director
CC transcript
Acq. announced
Director departure
NOVAVAX INC (NVAX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S."
08/08/2023 8-K Quarterly results
Docs: "Novavax Reports Second Quarter 2023 Financial Results and Operational Highlights"
08/08/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "At Market Issuance Sales Agreement by and among Novavax, Inc., Jefferies LLC and B. Riley Securities, Inc.",
"Opinion of Ropes & Gray LLP"
08/08/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Secu...
Docs: "SECURITIES SUBSCRIPTION AGREEMENT This SECURITIES SUBSCRIPTION AGREEMENT is made and entered into this 8th day of August, 2023 by and among Novavax, Inc., a Delaware corporation having a place of business at 21 Firstfield Rd., Gaithersburg, MD 20878 , and SK bioscience Co., Ltd., a company incorporated in the Republic of Korea having a place of business at 310 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 13494, Republic of Korea . The Company and SK shall each be hereinafter referred to as a “Party” and collectively as the “Parties”. WHEREAS, the Company and SK are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4 of the Securities Act of 1933, as amended ; and WHEREAS, the Company desires to issue to SK, shares of ..."
07/11/2023 8-K Quarterly results
07/07/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
05/09/2023 8-K Quarterly results
Docs: "Novavax Reports First Quarter 2023 Financial Results and Operational Highlights",
"Positive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccines Demonstrate Robust Immune Responses"
04/04/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "AMENDED AND RESTATED BY-LAWS"
03/22/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/14/2023 8-K Regulation FD Disclosure  Interactive Data
03/02/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/28/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Novavax Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights"
01/09/2023 8-K Quarterly results
12/28/2022 8-K Quarterly results
12/21/2022 8-K Quarterly results
12/19/2022 8-K Quarterly results
12/14/2022 8-K Quarterly results
12/09/2022 8-K/A Quarterly results
11/21/2022 8-K Termination of a Material Definitive Agreement  Interactive Data
11/08/2022 8-K Quarterly results
Docs: "Three Months Ended September 30, 2022 2021 Revenue: Product sales $ 626,091 $ -- Grants 106,273 135,007 Royalties and other 2,213 43,837 Total revenue 734,577 178,844 Expenses: Cost of sales 434,593 -- Research and development 304,297 408,195 Selling, general, and administrative 122,876 77,793 Total expenses 861,766 485,988 Income from operations Other income : Interest income Other income Income before income tax expense Income tax expense 2,472 6,041 Net income $ $ Net income per share Basic and diluted $ $ Weighted average number of common shares outstanding Basic and diluted 78,274 74,745 7 SELECTED CONSOLIDATED BALANCE SHEET DATA September 30, 2022 December 31, 2021 Cash and cash equivalents $ 1,280,581 $ 1,515,116 Total restricted cash 12,441 13,143 Total current assets 1,759,965..."
11/01/2022 8-K Quarterly results
10/06/2022 8-K Quarterly results
08/09/2022 8-K Quarterly results
Docs: "Novavax Reports Second Quarter 2022 Financial Results and Operational Highlights"
07/11/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
04/20/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Presentation of Novavax, Inc",
"Initial Results from Novavax’ COVID-19-Influenza Vaccine Trial are First to Show Feasibility of Combination Vaccine"
03/07/2022 8-K Quarterly results
03/01/2022 8-K Quarterly results
02/10/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Novavax Announces Positive Results of COVID-19 Vaccine in Pediatric Population of PREVENT-19 Phase 3 Clinical Trial"
02/07/2022 8-K Quarterly results
01/10/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "J.P. MORGAN 40 TH ANNUAL HEALTHCARE CONFERENCE NASDAQ: NVAX"
12/30/2021 8-K Entry into a Material Definitive Agreement  Interactive Data
12/20/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "European Commission Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy